Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Non-Current Assets (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Non-Current Assets data on record, last reported at $432.5 million in Q4 2025.

  • For Q4 2025, Non-Current Assets rose 3716.87% year-over-year to $432.5 million; the TTM value through Dec 2025 reached $908.6 million, up 1789.92%, while the annual FY2025 figure was $432.5 million, 3716.87% up from the prior year.
  • Non-Current Assets reached $432.5 million in Q4 2025 per TGTX's latest filing, up from $425.3 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $432.5 million in Q4 2025 and bottomed at $11.3 million in Q4 2024.
  • Average Non-Current Assets over 5 years is $65.1 million, with a median of $19.5 million recorded in 2021.
  • Peak YoY movement for Non-Current Assets: crashed 79.32% in 2023, then surged 3716.87% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $48.7 million in 2021, then plummeted by 48.01% to $25.3 million in 2022, then crashed by 53.97% to $11.6 million in 2023, then fell by 2.69% to $11.3 million in 2024, then soared by 3716.87% to $432.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $432.5 million in Q4 2025, $425.3 million in Q3 2025, and $38.7 million in Q2 2025.